The risk of developing heart failure was lower among patients who began treatment for type 2 diabetes with SGLT2 inhibitors compared with metformin. The odds of hospitalization and death were similar between groups. Taking SGLT2 inhibitors doubled the risk of genital infections.
Initiating treatment for type 2 diabetes with SGLT2 inhibitors reduces the risk of heart failure and disease-related death, a Harvard Medical School study has found. Treatment outcomes were compared with a group of patients receiving metformin. The results were published in the journal Annals of Internal Medicine.
The cumulative risk of hospitalization for heart failure and disease-related death was 20% lower among patients who started treatment for type 2 diabetes with SGLT2 inhibitors compared with participants who took metformin (hazard ratio (RR) was 0. 80). The likelihood of heart failure was 22% lower during treatment with SGLT2 inhibitors (RR = 0.78).
The cumulative risk of hospitalization for myocardial infarction and stroke and death from these diseases was similar in both groups of patients (HR = 0.96). The likelihood of having a stroke was also the same.
Taking SGLT2 inhibitors doubled the risk of developing genital infections (RR = 2.19). The safety of prescribing drugs in other parameters was similar.
The study included 8,613 patients who started diabetes treatment with an SGLT2 inhibitor (canagliflozin, empagliflozin, or dapagliflozin) and 17,226 people who received metformin as first-line therapy. The average follow-up time was 12 months.
Scientists assessed the effect of drugs on the risk of cardiovascular diseases and their safety, taking into account genital infections.